Transcranial Photobiomodulation for Autism, Early Infantile

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism, Early Infantile+4 More
Transcranial Photobiomodulation - Device
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a light therapy called transcranial photobiomodulation (tPBM) is safe and effective in improving autistic traits in kids with ADHD.

Eligible Conditions
  • Autism, Early Infantile
  • Attention Deficit Hyperactivity Disorder (ADHD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Baseline to Week 8

Baseline to Week 8
Efficacy-Attention Deficit Hyperactivity Disorder (Attention Deficit Hyperactivity Disorder Symptom Checklist)
Efficacy-Autism Spectrum Disorder (Social Responsiveness Scale-2)
Number of Participants that Report Adverse Events (Clinician-Rated Treatment Emergent Adverse Events Log)
Safety (The Transcranial Photobiomodulation Self-Report Questionnaire)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Transcranial Photobiomodulation
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Transcranial Photobiomodulation · No Placebo Group · N/A

Transcranial Photobiomodulation
Device
Experimental Group · 1 Intervention: Transcranial Photobiomodulation · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 8

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,678 Previous Clinical Trials
30,832,133 Total Patients Enrolled
8 Trials studying Autism, Early Infantile
858 Patients Enrolled for Autism, Early Infantile
T. Atilla Ceranoglu, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
54 Total Patients Enrolled

Eligibility Criteria

Age < 18 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
People who want to participate in the study must have a computer with a camera and a broadband internet connection.
were more likely to have greater than average improvements on multiple measures of functional outcomes
The study's participants are willing and able to cooperate by taking all tests and examinations, and they are also able to administer the study treatment as required by the protocol.
who are medically stable and have no significant medical history will be eligible to participate in this study
The participant fulfilled the diagnostic criteria for ADHD as established by the clinical diagnostic interview.
Before you can participate in this study, you need to understand what it is and what you will be asked to do

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Michigan100.0%
How old are they?
< 18100.0%
What site did they apply to?
Massachusetts General Hospital100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References